These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 30136384

  • 21. Add-on treatment with teneligliptin ameliorates glucose fluctuations and improves glycemic control index in Japanese patients with type 2 diabetes on insulin therapy.
    Tanaka S, Suzuki K, Aoki C, Niitani M, Kato K, Tomotsune T, Aso Y.
    Diabetes Technol Ther; 2014 Dec; 16(12):840-5. PubMed ID: 25144424
    [Abstract] [Full Text] [Related]

  • 22. Effects of Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes Mellitus in Open-Label, Marker-Stratified Randomized, Parallel-Group Comparison, Standard Treatment-Controlled Multicenter Trial (TOPLEVEL Study): Rationale and Study Design.
    Imazu M, Nakano A, Ito S, Hamasaki T, Kitakaze M, TOPLEVEL investigators and study coordinators.
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):363-370. PubMed ID: 30850916
    [Abstract] [Full Text] [Related]

  • 23. Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Ji L, Ma J, Lu W, Liu J, Zeng J, Yang J, Li W, Zhang X, Xiao X, Takayanagi G, Wang Y.
    J Diabetes Investig; 2021 Apr; 12(4):537-545. PubMed ID: 32810383
    [Abstract] [Full Text] [Related]

  • 24. Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).
    Takamiya Y, Okamura K, Shirai K, Okuda T, Kobayashi K, Urata H.
    Clin Exp Hypertens; 2020 Apr; 42(3):197-204. PubMed ID: 30974980
    [Abstract] [Full Text] [Related]

  • 25. Comparison of the administration of teneligliptin every day versus every other day in Japanese patients with type 2 diabetes: a randomized non-inferior test.
    Kamiko K, Aoki K, Kamiyama H, Taguri M, Shibata E, Ashiya Y, Minagawa F, Shinoda K, Nakajima S, Terauchi Y.
    J Clin Pharmacol; 2015 Feb; 55(2):144-51. PubMed ID: 25159300
    [Abstract] [Full Text] [Related]

  • 26. Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.
    Kadowaki T, Inagaki N, Watada H, Sasaki K, Mori-Anai K, Iwasaki T, Teranishi T.
    Adv Ther; 2022 Apr; 39(4):1642-1658. PubMed ID: 35138572
    [Abstract] [Full Text] [Related]

  • 27. Teneligliptin : expectations for its pleiotropic action.
    Morishita R, Nakagami H.
    Expert Opin Pharmacother; 2015 Feb; 16(3):417-26. PubMed ID: 25597385
    [Abstract] [Full Text] [Related]

  • 28. Comparison of the Effects of Teneligliptin and Sitagliptin, Two Dipeptidyl Peptidase 4 Inhibitors with Different Half-Lives, on Glucose Fluctuation and Glucagon-Like Peptide-1 in Type 2 Diabetes Mellitus.
    Kurozumi A, Okada Y, Sugai K, Torimoto K, Tanaka Y.
    J UOEH; 2018 Feb; 40(1):1-9. PubMed ID: 29553070
    [Abstract] [Full Text] [Related]

  • 29. Comparison of canagliflozin and teneligliptin on energy intake and body weight in Japanese patients with Type 2 diabetes: a subanalysis of the CANTABILE study.
    Isogawa M, Makino H, Son C, Nishimura K, Hirata T, Kasama S, Miyamoto Y, Noguchi M, Kasahara M, Hosoda K.
    BMC Endocr Disord; 2024 Aug 19; 24(1):153. PubMed ID: 39160513
    [Abstract] [Full Text] [Related]

  • 30. Effects of once-daily teneligliptin on 24-h blood glucose control and safety in Japanese patients with type 2 diabetes mellitus: a 4-week, randomized, double-blind, placebo-controlled trial.
    Eto T, Inoue S, Kadowaki T.
    Diabetes Obes Metab; 2012 Nov 19; 14(11):1040-6. PubMed ID: 22776014
    [Abstract] [Full Text] [Related]

  • 31. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes.
    Hashikata T, Yamaoka-Tojo M, Kakizaki R, Nemoto T, Fujiyoshi K, Namba S, Kitasato L, Hashimoto T, Kameda R, Maekawa E, Shimohama T, Tojo T, Ako J.
    Heart Vessels; 2016 Aug 19; 31(8):1303-10. PubMed ID: 26266630
    [Abstract] [Full Text] [Related]

  • 32. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial.
    Kim Y, Kang ES, Jang HC, Kim DJ, Oh T, Kim ES, Kim NH, Choi KM, Kim SR, You J, Kim SJ, Lee MK.
    Diabetes Obes Metab; 2019 Mar 19; 21(3):631-639. PubMed ID: 30362280
    [Abstract] [Full Text] [Related]

  • 33. A Dipeptidyl Peptidase-4 Inhibitor, Teneligliptin, Decreases Plasma Triglyceride-Rich Lipoprotein Remnants in Diabetic Patients with Chronic Kidney Disease Undergoing Hemodialysis.
    Homma K, Yoshizawa J, Shiina Y, Ozawa H, Igarashi M, Matsuoka T, Sasaki J, Yoshizawa M, Homma Y.
    Drugs R D; 2017 Sep 19; 17(3):397-402. PubMed ID: 28577292
    [Abstract] [Full Text] [Related]

  • 34. Evaluation of Teneligliptin a DPP4 Inhibitor in Terms of Efficacy and Safety with Respect to QT/QTc Prolongation in Patients with Type II Diabetes Mellitus (T2DM).
    Bhosle D, Chandekar B, Alimuddin S.
    J Assoc Physicians India; 2022 May 19; 70(5):11-12. PubMed ID: 35598125
    [Abstract] [Full Text] [Related]

  • 35. Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.
    Miya A, Nakamura A, Cho KY, Kawata S, Nomoto H, Nagai S, Sugawara H, Taneda S, Tsuchida K, Omori K, Yokoyama H, Takeuchi J, Aoki S, Kurihara Y, Atsumi T, Miyoshi H.
    J Diabetes Investig; 2021 Aug 19; 12(8):1395-1399. PubMed ID: 33325645
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
    Kadowaki T, Inagaki N, Kondo K, Nishimura K, Kaneko G, Maruyama N, Nakanishi N, Iijima H, Watanabe Y, Gouda M.
    Diabetes Obes Metab; 2017 Jun 19; 19(6):874-882. PubMed ID: 28177187
    [Abstract] [Full Text] [Related]

  • 38. The efficacy and safety of teneligliptin added to ongoing metformin monotherapy in patients with type 2 diabetes: a randomized study with open label extension.
    Bryson A, Jennings PE, Deak L, Paveliu FS, Lawson M.
    Expert Opin Pharmacother; 2016 Jul 19; 17(10):1309-16. PubMed ID: 27181910
    [Abstract] [Full Text] [Related]

  • 39. [Pharmacological and clinical profile of a novel DPP-4 inhibitor teneligliptin hydrobromide hydrate (TENELIA(®)].
    Goda M, Akahoshi F, Ishii S, Terata R, Hayashi Y.
    Nihon Yakurigaku Zasshi; 2013 Sep 19; 142(3):134-43. PubMed ID: 24025495
    [No Abstract] [Full Text] [Related]

  • 40. Review on Chemistry, Analysis and Pharmacology of Teneligliptin: A Novel DPP-4 Inhibitor.
    Sharma S, Sharma R, Hatware K, Patil K.
    Mini Rev Med Chem; 2020 Sep 19; 20(12):1091-1100. PubMed ID: 32107992
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.